Skip to content
value.today
Retractable Technologies, Inc. logo

Retractable Technologies, Inc.

RVP
$18 Mmarket cap on Oct 28, 2026-48.1% since Jan 2024
Compare
World rank
#24,683
Revenue
$38 M
For year ending December-2025
Net income
$-13 M
-32.8% margin
SEC filing
Employees
201
As of March 9, 2026
SEC filing

Retractable Technologies, Inc. in brief

Retractable Technologies, Inc. is a listed company in the Medical Instruments industry, based in Little Elm, Texas, USA. Its market value was $18 M on 28 October 2026, which makes it the 24,683rd largest listed company in the world and the 4,177th largest in the USA on this site. In the year to December 2025 it had sales of $38 M and a net loss of $13 M. It employs about 201 people and Thomas J. Shaw is its chief executive. Its largest product and service lines by sales in 2025 were Syringes (65%), EasyPoint Needles (31%) and Blood Collection Products (4%). Its shares trade under the symbol RVP (NYSE).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Retractable Technologies, Inc.

Retractable Technologies, Inc. was incorporated in Texas in 1994. Our business is the manufacturing and marketing of safety medical products (predominately syringes) for the healthcare industry. We have manufacturing facilities in Little Elm, Texas and use manufacturers in China as well. Our syringes are well-suited for administering vaccinations.

On September 13, 2024, the Office of the U.S. Trade Representative revealed final adjustments to increase tariffs on certain goods imported from China under Section 301 of the Trade Act of 1974. Among those products included were syringes and needles, at a rate of 100%. Beginning in early 2025 and throughout much of the year, additional widespread tariffs were imposed on most products imported into the U.S. citing authority under the International Emergency Economic Powers Act. Those tariffs were in addition to the Section 301 tariffs which existed at the time. Throughout 2025, the prevailing tariff rates on various products and certain countries of origin, including many of our products, fluctuated greatly. These fluctuations negatively impacted our ability to predict the cost of importing certain goods or groups of goods and negatively impacted our business. In February 2026, the U.S. Supreme Court ruled that the President’s use of IEEPA to impose reciprocal tariffs exceeded his authority and that the IEEPA tariffs must be vacated. Looking forward after the Supreme Court’s ruling, the 2024 Section 301 tariff of 100% on syringes and needles from China remains unchanged. Additionally, following the Supreme Court’s ruling on the tariffs imposed under IEEPA, effective February 20, 2026 a 10% ad valorem duty went into effect under Section 122 of the Trade Act, which is in addition to the above-mentioned Section 301 tariffs.

From the company's annual report filed with the US SEC: read the report

Retractable Technologies, Inc. timeline

4 events, 2000–2021
  1. 2000
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2001
  4. 🔔
    · approximate
    Initial public offering on NYSE
  5. 2021
  6. 💰
    Record revenue of $188 million
    FY2021, the highest of the 8 years on record.
  7. 💰
    Record net income of $56 million
    FY2021, the highest profit of the 4 years on record.

Events of Retractable Technologies, Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$98 M$196 M$294 M$392 M2020202120222023202420252026

World rank over time

▼ down 2,653 places since 2020
2020-01-01: #22046#22,04620202021-01-01: #12783#12,78320212022-01-07: #18404#18,40420222022-12-25: #24546#24,54620222023-07-30: #27093#27,09320232024-01-05: #26683#26,68320242026-03-08: #12037#12,03720262026-08-01: #21676#21,67620262026-10-28: #24699#24,6992026

Rank in USA: #4,137 (Jan 2020) · #2,796 (Jan 2021) · #3,763 (Jan 2022) · #4,692 (Dec 2022) · #4,958 (Jul 2023) · #4,222 (Jan 2024) · #2,304 (Mar 2026) · #3,938 (Aug 2026) · #4,180 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.5×
Price / book
0.2×
Free cash flow yield
-73.6%
Net margin (TTM)
-10.0%
Operating margin
-55.3%
Return on equity
-4.5%
Liabilities / assets
47.9%
Net debt
$-2M
Revenue growth
+15.8%
R&D / revenue
1.8%
Revenue per employee
$190 K
Profit per employee
$-63 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $33M, net income $-1M$33MFY18Fiscal year ending Dec 2019: revenue $42M, net income $3M$42MFY19Fiscal year ending Dec 2020: revenue $82M, net income $24M$82MFY20Fiscal year ending Dec 2021: revenue $188M, net income $56M$188MFY21Fiscal year ending Dec 2022: revenue $95M, net income $5M$95MFY22Fiscal year ending Dec 2023: revenue $44M, net income $-7M$44MFY23Fiscal year ending Dec 2024: revenue $33M, net income $-12M$33MFY24Fiscal year ending Dec 2025: revenue $38M, net income $-13M$38MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$38M+15.8%$-21M$-13M-32.8%
Dec 2024$33M-24.2%$-21M$-12M-36.0%
Dec 2023$44M-54.0%$-11M$-7M-16.1%
Dec 2022$95M-49.7%$-1M$5M5.4%
Dec 2021$188M+130.1%$73M$56M29.8%
Dec 2020$82M+95.8%$24M$24M29.6%
Dec 2019$42M+25.6%$3M$3M7.5%
Dec 2018$33M—$-1M$-1M-4.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-7M——$-0.43—
Dec 2024$-12M$1M$-13M$-0.40—
Dec 2023$3M$1M$2M$-0.24—
Dec 2022$17M$17M$-0M$0.15—
Dec 2021$33M$58M$-26M$1.63—
Dec 2020$19M$21M$-2M$0.80—
Dec 2019$2M$1M$2M$0.07—
Dec 2018$-1M$0M$-2M$-0.06—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$34M
Net income, trailing 12 months
$-3M
RevenueNet income
Three months to Sep 2024: revenue $10M, net income $-2M$10MSep ’24Three months to Dec 2024 (from the annual report): revenue $9M, net income $4M$9MDec ’24Three months to Mar 2025: revenue $8M, net income $-11M$8MMar ’25Three months to Jun 2025: revenue $10M, net income $-0M$10MJun ’25Three months to Sep 2025: revenue $10M, net income $0M$10MSep ’25Three months to Dec 2025 (from the annual report): revenue $9M, net income $-2M$9MDec ’25Three months to Mar 2026: revenue $7M, net income $-4M$7MMar ’26Three months to Jun 2026: revenue $7M, net income $3M$7MJun ’26

Latest quarter to Jun 2026: revenue $7M (-31.1% on a year earlier), net income $3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Retractable Technologies, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$38 M
Operating income
$-21 M
Net income
$-13 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$143 M
Total liabilities
$68 M
Total equity
$74 M

As of December-2025

Top 33 institutional investors in Retractable Technologies, Inc.#

As of Sep 30, 2026
33 institutions held 2.5 M shares (about 8.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 7.6%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Retractable Technologies, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC581,7360 (0.00%)1.94%$0 MNov 13, 2026
2Eversept Partners, LP580,9190 (0.00%)1.94%$0 MNov 16, 2026
3Renaissance Technologies LLC407,389-34,018 (-7.71%)1.36%$0 MNov 12, 2026
4BlackRock, Inc.241,1210 (0.00%)0.81%$0 MNov 13, 2026
5Geode Capital Management, LLC118,156-2,849 (-2.35%)0.39%$0 MNov 6, 2026
6Bridgeway Capital Management, LLC87,444-1,099 (-1.24%)0.29%$0 MNov 16, 2026
7Vanguard Fiduciary Trust Co85,2600 (0.00%)0.28%$0 MNov 13, 2026
8Empowered Funds, LLC63,014New0.21%$0 MNov 13, 2026
9State Street Corp59,7960 (0.00%)0.20%$0 MNov 12, 2026
10LPL Financial LLC46,116-1,450 (-3.05%)0.15%$0 MNov 6, 2026
11Citadel Advisors LLC44,367-42,966 (-49.20%)0.15%$0 MNov 16, 2026
12WealthTrust Axiom LLC42,333-9,000 (-17.53%)0.14%$0 MNov 10, 2026
13Avidian Wealth Enterprises, LLC30,8000 (0.00%)0.10%$0 MOct 8, 2026
14Northern Trust Corp28,4440 (0.00%)0.10%$0 MNov 16, 2026
15Frisch Financial Group, Inc.19,0000 (0.00%)0.06%$0 MNov 10, 2026
16Susquehanna International Group, LLP12,318-66,539 (-84.38%)0.04%$0 MNov 16, 2026
17Pasadena Private Wealth, LLC10,4000 (0.00%)0.03%$0 MNov 10, 2026
18CX Institutional7,0000 (0.00%)0.02%$0 MOct 2, 2026
19Jones Financial Companies Lllp6,4000 (0.00%)0.02%$0 MNov 13, 2026
20UBS Group AG5,987+1,648 (+37.98%)0.02%$0 MNov 10, 2026
21Vanguard Global Advisers, LLC5,8130 (0.00%)0.02%$0 MNov 13, 2026
22Morgan Stanley3,430-100 (-2.83%)0.01%$0 MNov 13, 2026
23Rockefeller Capital Management L.P.2,5000 (0.00%)0.01%$0 MNov 13, 2026
24Tower Research Capital LLC (TRC)2,193-445 (-16.87%)0.01%$0 MNov 16, 2026
25Performa Ltd (US), LLC1,7500 (0.00%)0.01%$0 MNov 5, 2026
Show all 33: investors 26 to 33
Institutional investors 26 to 33 in Retractable Technologies, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Royal Bank Of Canada1,099New0.00%$0 MNov 16, 2026
27Citigroup Inc1,073New0.00%$0 MNov 4, 2026
28Wells Fargo & Company/mn5000 (0.00%)0.00%$0 MNov 16, 2026
29IFP Advisors, Inc41New0.00%$0 MOct 16, 2026
30Allworth Financial LP25New0.00%$0 MNov 17, 2026
31Northwestern Mutual Wealth Management Co18New0.00%$0 MNov 13, 2026
32SBI Securities Co., Ltd.80 (0.00%)0.00%$0 MOct 22, 2026
33Barclays PLC60 (0.00%)0.00%$0 MNov 6, 2026

Mutual funds holding Retractable Technologies, Inc.#

7 funds hold shares worth $1 M (about 2.6% of the company). Since their previous reports 1 added shares and 0 sold, buying $0 M net.
Mutual funds holding Retractable Technologies, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.412,203$0 M1.4%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.169,533$0 M0.57%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC80,434$0 M0.27%<0.01%+35%May 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC64,113$0 M0.21%0.03%no changeJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC31,995$0 M0.11%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC15,739$0 M0.05%<0.01%no changeMay 31, 2026
🇺🇸 Omni Small-Cap Value FundBridgeway Capital Management, LLC9,430$0 M0.03%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Retractable Technologies, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
9
since
$132 K$0Nov 2023: bought $18 K (9 trades), sold $0 (0 trades)Nov 23Dec 2023: bought $54 K (19 trades), sold $0 (0 trades)Jan 2024: bought $61 K (18 trades), sold $0 (0 trades)Feb 2024: bought $81 K (10 trades), sold $0 (0 trades)Mar 2024: bought $29 K (8 trades), sold $0 (0 trades)MarApr 2024: bought $76 K (8 trades), sold $0 (0 trades)May 2024: bought $132 K (9 trades), sold $0 (0 trades)Jun 2024: bought $24 K (4 trades), sold $0 (0 trades)Jul 2024: bought $49 K (7 trades), sold $0 (0 trades)JulAug 2024: bought $60 K (7 trades), sold $0 (0 trades)Sep 2024: bought $118 K (8 trades), sold $0 (0 trades)Oct 2024: bought $39 K (6 trades), sold $0 (0 trades)Nov 2024: bought $39 K (5 trades), sold $0 (0 trades)NovDec 2024: bought $30 K (8 trades), sold $0 (0 trades)Jan 2025: bought $73 K (6 trades), sold $0 (0 trades)Feb 2025: bought $71 K (6 trades), sold $0 (0 trades)Mar 2025: bought $23 K (5 trades), sold $0 (0 trades)MarApr 2025: bought $46 K (6 trades), sold $0 (0 trades)May 2025: bought $123 K (11 trades), sold $0 (0 trades)Jun 2025: bought $39 K (5 trades), sold $0 (0 trades)Jul 2025: bought $38 K (5 trades), sold $0 (0 trades)JulAug 2025: bought $117 K (10 trades), sold $0 (0 trades)Sep 2025: bought $27 K (5 trades), sold $0 (0 trades)Oct 2025: bought $128 K (7 trades), sold $0 (0 trades)Nov 2025: bought $11 K (3 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Retractable Technologies, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Thomas J. ShawPRESIDENT AND CEO, Director, 10% ownerBuy10b5-1 plan+5,731$0.770$4 K15.83 MForm 4
filed Thomas J. ShawPRESIDENT AND CEO, Director, 10% ownerBuy10b5-1 plan+100$0.810$8115.83 MForm 4
filed Thomas J. ShawPRESIDENT AND CEO, Director, 10% ownerBuy10b5-1 plan+7,500$0.830$6 K15.83 MForm 4
filed Thomas J. ShawPRESIDENT AND CEO, Director, 10% ownerBuy10b5-1 plan+15,000$0.860$13 K15.82 MForm 4
filed Thomas J. ShawPRESIDENT AND CEO, Director, 10% ownerBuy10b5-1 plan+35,000$0.920$32 K15.80 MForm 4
filed Thomas J. ShawPRESIDENT AND CEO, Director, 10% ownerBuy10b5-1 plan+34,506$0.940$32 K15.77 MForm 4
filed Thomas J. ShawPRESIDENT AND CEO, Director, 10% ownerBuy10b5-1 plan+356$0.950$33815.73 MForm 4
filed Thomas J. ShawPRESIDENT AND CEO, Director, 10% ownerBuy10b5-1 plan+10,000$0.960$10 K15.73 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Retractable Technologies, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
22,900
0.1% of shares · 1.13 days to cover
Buybacks, Q4 2022
$4.8M
Q4 2022
Shares sold short, last 24 reportsAll stocks →
Retractable Technologies, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2022Q4 2022$4.8M
Q3 2022Q3 2022$0M
Q2 2022Q2 2022$0.3M
Q1 2022Q1 2022$2.5M
Q4 2021Q4 2021$2.4M
Q3 2021Q3 2021$2.7M
Q2 2021Q2 2021$0.2M
Q4 2013Q4 2013$0M
Q3 2013Q3 2013$0.5M
Q2 2013Q2 2013$0.3M
Q1 2013Q1 2013$0.1M
Q4 2012Q4 2012$0M

Fails to deliver

  • : 1,189 shares at $0.59
  • : 149 shares at $0.73
  • : 287 shares at $0.66
  • : 1,444 shares at $0.70
  • : 3,004 shares at $0.70

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Retractable Technologies, Inc. scorecard#

Passes 7 of the 22 checks that could be worked out: strongest in financial health (3 of 5), weakest in profitability (0 of 5). Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.2×Price to book 0.2× against Medical Instruments's median of 3.9×.
    • ✓Price to sales below its peers' median0.5×Price to sales 0.5× against Medical Instruments's median of 3.0×.
    • ✗Free cash flow yield above 5%-73.6%Free cash flow is -73.6% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 6
    • ✓Revenue grew in the newest year15.8%Revenue up 15.8% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-26.1%-26.1% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-26.1%-26.1% a year against Medical Instruments's median of 5.0% (37 companies).
    • ✗Earnings per share grew in the newest year-0.43 vs -0.40Diluted EPS -0.43 in fiscal 2025 against -0.40 the year before (report's currency).
    • ✗Net income higher than five years earlier-$13 M-$13 M in fiscal 2025 against $24 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability0 of 5
    • ✗Profitable in the newest year-$13 MNet income -$13 M in fiscal 2025.
    • ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-55.3%-55.3% against Medical Instruments's median of 7.2% (46 companies).
    • ✗Return on equity above 15%-15.6%-15.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-55.3%-55.3% in fiscal 2025 against -0.9% in 2022.
  • Financial health3 of 5
    • ✓Short-term assets cover short-term liabilities6.6×Current ratio 6.57 at the end of fiscal 2025.
    • ✓Debt below equity0.0×Debt to equity 0.01 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $2 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone0.52Z-score 0.52 (distress zone) for fiscal 2025.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year0.0%Diluted shares down 0.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Medical Instruments, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Retractable Technologies, Inc.'s statements, beside the median of Medical Instruments.

Retractable Technologies, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-55.3%7.2%
Net margin-32.9%3.8%
Return on equity-15.6%3.5%
Revenue growth, 3 years a year-26.1%5.0%
Revenue growth15.8%8.9%
Debt to equity0.01×0.46×

4of 9on the Piotroski tests of financial strength

  • Net loss of $13 million, the 3th loss-making year in a row.
  • More cash than debt: net cash of $2 million.

Retractable Technologies, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Retractable Technologies, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue383344951888242333430
Cost of revenue38343467934528232519
Gross profit0.0−1.09.1289537141010.010
Research and development0.70.70.60.50.90.60.50.60.70.6
Selling and marketing6.85.85.74.54.54.14.24.44.74.0
General and administrative13141424178.36.46.8r8.48.8
Operating expenses2120212923131112r1414
Operating income−21−21−11−0.973243.0−1.3r−3.8−3.5
Interest and finance income—————2.30.40.2r0.10.0
Interest expense and finance costs0.10.10.20.20.20.30.20.20.20.2
Income before tax−12−3.5−8.95.275263.2−1.4−3.9−3.7
Income tax0.38.4−1.90.1191.90.0−0.0−0.20.0
Net income including minority interests−13−12−7.05.156243.1−1.3−3.7−3.7
Net income attributable to shareholders−13−12−7.05.156243.1−1.3−3.7−3.7
Earnings per share, basic-0.43-0.40-0.240.151.650.800.07-0.06-0.14-0.15
Earnings per share, diluted-0.43-0.40-0.240.151.630.800.07-0.06-0.14-0.15
Shares, weighted average (basic)30303033343333333229
Shares, weighted average (diluted)30303033343333333229
Balance sheet
Cash and cash equivalents2.64.2132029185.99.61516
Receivables7.97.8114.83521r6.64.95.13.3
Inventory1719182121107.57.56.27.0
Other current assets0.70.81.01.3r0.70.70.60.60.40.2
Current assets63737889105692826r2727
Property, plant and equipment798793100883111111112
Right-of-use (leased) assets—————0.00.10.2——
Total assets1431611801962061053937r3839
Accounts payable5.34.34.86.420165.05.45.04.5
Debt due within a year—0.30.30.30.31.00.30.40.40.4
Current liabilities9.68.89.41235288.38.6r7.97.2
Long-term debt—0.91.21.51.82.72.42.63.13.5
Lease liabilities (non-current)———————0.1——
Total liabilities68748089107551111r1111
Retained earnings1427394641−9.7−34−37−36−32
Shareholders' equity748799107995029262728
Total liabilities and equity1431611801962061053937r3839
Shares outstanding30303030333433333330
Cash-flow statement
Depreciation and amortization7.87.67.54.61.30.80.90.90.80.9
Share-based compensation—0010r3.70000.70.4
Cash from operating activities−7.1−122.81733192.2−1.2−2.9−0.8
Capital expenditure—−1.4−0.9−17−58−21−0.6−0.4−0.1−1.9
Cash from investing activities6.03.7−11−31−63−19−5.3−3.4−0.1−1.9
Debt issued—————1.4———0.5
Debt repaid−0.3−0.3−0.3−0.3−0.3−0.3−0.4−0.4−0.4−0.3
Shares issued————5.3———2.4—
Shares bought back———−7.6−5.3—————
Cash from financing activities−0.6−0.50.95.04212−0.6−0.71.70.9
Change in cash−1.6−8.4−7.1−9.41212−3.7−5.2−1.3−1.8
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Retractable Technologies, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Syringes$25 M65%
  • EasyPoint Needles$12 M31%
  • Blood Collection Products$1 M3.6%
  • Other Products$0 M0.1%

Business segments

  • Single reportable segment$38 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Retractable Technologies, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.2 M
Thomas J. Shaw
Other top executives, average
$304 K
the CEO earned 4× this
$100 invested is now
$7
peer group: $115
Retractable Technologies, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Thomas J. Shaw$1.2 M$1.2 M$304 K$7 (peers $115)
2024Thomas J. Shaw$1.2 M$1.2 M$279 K$7 (peers $107)
2023Thomas J. Shaw$1.1 M$1.1 M$280 K$10 (peers $99)
2022Thomas J. Shaw$1.1 M$8.6 M$276 K$15 (peers $97)
2021Thomas J. Shaw$11.5 M$4.0 M$1.3 M$65 (peers $121)

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Retractable Technologies, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling

Auditor changed 1 · Shareholder vote 3

Retractable Technologies, Inc.: events reported to the SEC
FiledWhat happenedFiling
Shareholder vote8-K
Auditor changed8-K
Shareholder vote8-K
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of May 13, 2026

Lobbying by Retractable Technologies, Inc.#

$120 K spent on lobbying the US Congress and federal agencies in 2022, most often on health issues and manufacturing.

Lobbying, 2022
$120 K
#1,084 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2022
2026 so far
—
  • Health Issues3 reports
  • Manufacturing3 reports

Lobbying firms hired in 2022

Tiber Creek Group $120 K

Retractable Technologies, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2022$120 K—4
2021$180 K—4
2020$110 K—5

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Retractable Technologies, Inc.”, “Retractable Technologies, Inc. (RTI)” and “Retractable Technologies, Inc. (RT)”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Retractable Technologies, Inc.#

1 labor condition applications certified in fiscal 2024 for 1 positions, at a median wage of $73 K a year.

Certified, FY2024
1
#1,981 among companies on value.today
Worker positions
1
Median wage offered
$73 K
a year, full-time
Applications filed
2
Retractable Technologies, Inc.: most frequent H-1B job titles in fiscal 2024
Job titlePositionsMedian wage offered
Biomedical Device Compliance and Regulatory AffairBioengineers and Biomedical Engineers1$73 K

Where: Little Elm, TX 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Retractable Technologies Inc and Retractable Technologies Inc

Product recalls by Retractable Technologies, Inc.#

1 recalls since 2015, 477,600 units in the notices that give a number. Medical devices (FDA): 1.

Retractable Technologies, Inc.: product recalls
DateWhat and whyUnitsNotice
EasyPoint Needle, 25G x 5/8", REF: 82091The needle cannula of a retractable needle may detach from the needle holder in the patient.Medical devicesClass II477,600Z-1293-2024

Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness

How Retractable Technologies, Inc. compares in Medical Instruments

  • Market cap$18 M · higher than 3% of 116
  • Revenue$38 M · higher than 13% of 120
  • Net margin-10.0% · higher than 14% of 114
  • Revenue growth15.8% · higher than 73% of 49
  • Price / sales0.5× · lower than 95% of 85
  • Price / book0.2× · lowest of 84
  • FCF yield-73.6% · higher than 5% of 39

Peer comparison · Medical Instruments

CompanyMarket capP/ENet marginRev. growth
Retractable Technologies, Inc.🇺🇸$18 M—-10.0%+15.8%
Intuitive Surgical, Inc.🇺🇸$155.6 B52.6×25.5%+20.5%
EssilorLuxottica S.A.🇫🇷$88.0 B32.1×8.1%+4.5%
HOYA Corporation🇯🇵$56.2 B32.8×25.4%—
Becton, Dickinson and Company🇺🇸$54.0 B57.4×4.2%+8.2%
Alcon Inc.🇨🇭$37.1 B37.9×9.4%+4.9%
ResMed Inc.🇺🇸$35.3 B22.1×27.8%+9.8%
West Pharmaceutical Services, Inc.🇺🇸$27.1 B42.4×18.8%+6.3%
Terumo Corporation🇯🇵$24.9 B27.0×12.0%—

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 9, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Retractable Technologies, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Retractable Technologies, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Retractable Technologies, Inc.? Suggest a correction